following a full submission assessed under the end of life and orphan equivalent medicine process:
durvalumab (Imfinzi®) is accepted for use within NHSScotland.
Indication under review: in combination with gemcitabine and cisplatin for the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer.
In a phase III study, addition of durvalumab to current standard of care chemotherapy significantly improved overall survival and progression-free survival in adults receiving first-line treatment for advanced or metastatic biliary tract cancer.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Download detailed advice768KB (PDF)
- Medicine name:
- durvalumab (Imfinzi)
- SMC ID:
In combination with gemcitabine and cisplatin for the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer (BTC).
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 13 November 2023